Results 1 to 10 of about 780 (113)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance [PDF]

Human Vaccines and Immunotherapeutics, 2023
Off-treatment HBsAg reversion occurs in a considerable number of chronic hepatitis B(CHB) patients after IFN(interferon)-induced HBsAg clearance. HBV vaccination protects the general population against HBV infection.
Minghao Cai
exaly   +5 more sources

End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation [PDF]

Frontiers in Cellular and Infection Microbiology, 2023
BackgroundHepatitis B surface antigen (HBsAg) loss, namely, the functional cure, can be achieved through the pegylated interferon (PEG-IFN)-based therapy. However, it is an unignorable fact that a small proportion of patients who achieved functional cure
He Jingjing, Yifei Guo, Jingjing He
exaly   +4 more sources

Sustained HBsAg clearance induced by pegylated interferon α-2b in HBeAg-negative patients with low baseline HBsAg [PDF]

Frontiers in Cellular and Infection Microbiology
BackgroundPatients with low HBsAg levels, HBeAg-negative status and undetectable HBV DNA are recognized as the advantaged population for pegylated interferon α-2b (Peg-IFNα-2b) therapy.
Chaojing Wen, Taiyu He, Guanhua Zha, Aoyi Li, Zhiyi Wang, Zhi Zhou, Dachuan Cai, Dazhi Zhang, Mingli Peng, Xiaofeng Shi, Hong Ren   +10 more
doaj   +2 more sources

Discussion on the duration of response following HBsAg clearance in patients with chronic hepatitis B treated with PegIFNα-2b [PDF]

Frontiers in Immunology
AimFunctional cure strategies based on interferon therapy for chronic hepatitis B (CHB) are gaining increasing attention among clinicians. However, studies investigating the duration of response after achieving HBsAg clearance with interferon treatment ...
Tao Wang, Fei Tang, Fenghui Li, Jing Chen, Fei Yan, Qin Du, Weili Yin, Jing Liang, Lei Liu, Fang Wang, Baiguo Xu, Qing Ye, Huiling Xiang   +12 more
doaj   +2 more sources

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation [PDF]

BMC Gastroenterology, 2023
Background Since hepatitis B surface antigen (HBsAg) loss is rarely achieved with nucleos(t)ide analog (NA) treatment, most patients require life-long NA treatment. Previous studies have shown that some patients remain virologically responsive even after
Yandi Xie, Minghui Li, Xiaojuan Ou, Sujun Zheng, Yinjie Gao, Xiaoyuan Xu, Ying Yang, Anlin Ma, Jia Li, Yuemin Nan, Huanwei Zheng, Juan Liu, Lai Wei, Bo Feng   +13 more
doaj   +2 more sources

The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment [PDF]

Virology Journal
Background Hepatitis B surface antigen (HBsAg) loss is regarded as a pivotal criterion for assessing functional cure in patients diagnosed chronic hepatitis B (CHB).
Wencong Zhang, Jia Chen, Wenjin Sun, Nana Xie, Fangbing Tian, Qiurong Ruan, Jianxin Song   +6 more
doaj   +2 more sources

Dynamic changes of chronic hepatitis B patient with loss of surface antigen: a case report [PDF]

BMC Infectious Diseases
Background Hepatitis B virus (HBV) infection remains a significant global health challenge, particularly in regions like China, where the prevalence of HBV carriers is high.
Chong Wang, Lin Lin, Da Peng Ding
doaj   +2 more sources

Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection [PDF]

Frontiers in Immunology, 2022
ObjectiveTo investigate the sustained virological response and relapse in chronic hepatitis B (CHB) patients with hepatitis B e antigen (HBeAg) positive after stopping oral antiviral drugs, and to monitor the disease progression and the incidence of ...
Fangfang Sun, Fangfang Sun, Zhenhua Li, Leiping Hu, Wen Deng, Tingting Jiang, Shiyu Wang, Xiaoyue Bi, Huihui Lu, Huihui Lu, Liu Yang, Yanjie Lin, Zhan Zeng, Ge Shen, Ruyu Liu, Min Chang, Shuling Wu, Yuanjiao Gao, Hongxiao Hao, Mengjiao Xu, Xiaoxue Chen, Lu Zhang, Yao Lu, Jianping Dong, Yao Xie, Yao Xie, Minghui Li, Minghui Li   +27 more
doaj   +2 more sources

Meta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment. [PDF]

Aliment Pharmacol Ther
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Poola S, Kratzer M, Sewell K, Yang Z, Tillmann HL.   +4 more
europepmc   +2 more sources

Disrupting Viral Persistence: CRISPR/Cas9-Based Strategies for Hepatitis B and C Treatment, and Challenges. [PDF]

J Cell Mol Med
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Li MF, Zubair A, Wdidi S, He S.
europepmc   +2 more sources